Sanford Burnham
  • Sanford Burnham
  • Twitter
  • Facebook
  • Youtube
  • Navigate Sanford-Burnham
    • Main Site
    • Our Mission
    • Research
    • Talent
    • Technology
    • Training & Education
    • Our Supporters
    • News

Beaker

Sanford-Burnham Science Blog

Subscribe

Top 10 most-read blog posts of 2012: #2

by Bruce Lieberman on December 30, 2012 at 5:00 am | 0 Comments
Full Article
Drug-like chemical compound LTV-1 (foreground) blocks the action of mutant LYP protein in human immune cells, providing a potential new therapeutic for autoimmune diseases.

Drug-like chemical compound LTV-1 (foreground) blocks the action of mutant LYP protein in human immune cells, providing a potential new therapeutic for autoimmune diseases.

New insight into mechanisms behind autoimmune diseases suggests a potential therapy

Originally published March 18, 2012

Autoimmune diseases, such as Type I diabetes and rheumatoid arthritis, are caused by an immune system gone haywire, where the body’s defense system assaults and destroys healthy tissues. A mutant form of a protein called LYP has been implicated in multiple autoimmune diseases, but the precise molecular pathway involved has been unknown. Now, in a paper published March 18 in Nature Chemical Biology, Sanford-Burnham researchers show how the errant form of LYP can disrupt the immune system. In doing so, they also found a potential new therapy for autoimmune diseases—a chemical compound that appears to inhibit this mutant protein.

Read More

New insight into mechanisms behind autoimmune diseases suggests a potential therapy

by Bruce Lieberman on March 18, 2012 at 11:00 am | 3 Comments
Full Article
Drug-like chemical compound LTV-1 (foreground) blocks the action of mutant LYP protein in human immune cells, providing a potential new therapeutic for autoimmune diseases.

Drug-like chemical compound LTV-1 (foreground) blocks the action of mutant LYP protein in human immune cells, providing a potential new therapeutic for autoimmune diseases.

Autoimmune diseases, such as Type I diabetes and rheumatoid arthritis, are caused by an immune system gone haywire, where the body’s defense system assaults and destroys healthy tissues. A mutant form of a protein called LYP has been implicated in multiple autoimmune diseases, but the precise molecular pathway involved has been unknown. Now, in a paper published March 18 in Nature Chemical Biology, Sanford-Burnham researchers show how the errant form of LYP can disrupt the immune system. In doing so, they also found a potential new therapy for autoimmune diseases—a chemical compound that appears to inhibit this mutant protein.

Read More

New insights into children’s health

by Heather Buschman, Ph.D. on November 22, 2010 at 10:54 am | 2 Comments
Full Article

San Diego’s Rady Children’s Hospital recently brought together an all-star cast of speakers for a symposiumon pediatric translational research – laboratory research that could be “translated” into therapies for sick children. This was the ideal place to bring laboratory scientists together with physicians. The close connection to patients was clear, as kids played in the hall outside the conference room, paramedics checked out the posters and doctors used the wall phones to return pager calls and provide consultations.What did they talk about? A little bit of everything that’s hot in pediatric research: brain cancer, leukemia, rare genetic diseases, stem cell therapies and re-wiring the immune response to fight disease.

One of Sanford-Burnham’s newest recruits, stem cell expert Dr. Robert Wechsler-Reya, was there. Dr. Wechsler-Reya hasn’t finished his move to San Diego yet, but he did not want to miss the opportunity to connect with his colleagues in stem cell research and pediatric medicine.

Read More

Study raises questions about lymphoma drugs

by Heather Buschman, Ph.D. on October 20, 2010 at 11:52 am | 0 Comments
Full Article
Dr. Robert Rickert

Dr. Robert Rickert

Lymphoma is a cancer of the immune system. White blood cells divide again and again, spreading abnormally throughout the body. Lymphomas can arise from two types of white blood cells, T cells or B cells, which divide uncontrollably when the molecular mechanisms that keep them in check go awry. A new study led by Dr. Robert Rickert, professor and director of Sanford-Burnham’s Inflammatory Diseases Program, explores the roles of two enzymes, called SHIP and PTEN, in B cell growth and proliferation.

“PTEN usually gets all the attention,” Dr. Rickert explained. “But here we show for the first time that SHIP is also a major tumor suppressor in B cells.”

The results, published this week in The Journal of Experimental Medicine, show that SHIP and PTEN act cooperatively to suppress B cell lymphoma. This new information could impact several anti-lymphoma therapies currently in development.

Read More

A tale of two SHEPherds

by Heather Buschman, Ph.D. on October 18, 2010 at 12:32 pm | 3 Comments
Full Article

A paper published online this week in the Proceedings of the National Academy of Sciences (PNAS) highlights a collaboration between two Sanford-Burnham scientists, one an immunologist in the Infectious and Inflammatory Disease Center and the other a cell communication expert in the Cancer Center.

Dr. Robert Rickert studies B cells, a type of white blood cell in the immune system that produces antibodies to neutralize foreign particles. Because they move around the body, immune cells are oddities compared to other types of cells.

“Other scientists worry about a process called anoikis, in which wandering cells are programmed to self-destruct,” Dr. Rickert explains. “In contrast, only some populations of B cells stay put, like those found in the marginal zone of the spleen.”

So it caught his attention one day when he heard his colleague Dr. Elena Pasquale talk about her work on integrins, a family of proteins located on the surface of many cell types. Integrins carry signals back and forth between the inside and outside of cells, allowing cells to adhere to their surroundings or other cells. Dr. Rickert knew that integrin signaling is required for B cells to remain in a particular region of the spleen, known as the marginal zone, but not why.

Read More

Search

Find more information

  • About Beaker
  • Contact us
  • Donate

Please take a quick survey

Which of these items describes you?

Select all that apply. (Question 1 of 5)

Categories

  • Basic Research
  • Cancer
    • Apoptosis & Cell Death Research
    • Signal Transduction
    • Tumor Development
    • Tumor Microenvironment
  • Children's Health
    • Genetic Diseases
    • Muscle Development & Regeneration
    • RNA Biology
  • Diabetes & Obesity
    • Cardiovascular Pathobiology
    • Metabolic Signaling & Disease
  • Drug Discovery
  • Events
  • Graduate School of Biomedical Sciences
  • Grants
  • Infectious & Inflammatory Diseases
    • Bioinformatics & Systems Biology
    • Infectious Diseases
    • Inflammatory Diseases
  • Nanomedicine
  • Neuroscience, Aging, & Stem Cells
    • Degenerative Diseases
    • Development & Aging
    • Stem Cells
  • Other
  • People
  • Sanford-Burnham Supporters
  • Translational Medicine

Search by Keyword

Alzheimer's disease CCRA CIRM collaboration commitment communication community Conrad Prebys Center for Chemical Genomics Daniel Kelly Erkki Ruoslahti Evan Snyder Florida Hospital Fred Levine Genetic Disease Program Guy Salvesen Hudson Freeze John Reed Kristiina Vuori La Jolla Lake Nona Metabolic Signaling metabolism NIH Orlando personalized medicine Prebys Center press proteins Rare Diseases Rare disease symposium research publications Robert Wechsler-Reya Santa Barbara Sara Courtneidge Stem Cells Steven Smith Stuart Lipton T. Denny Sanford technology Translational Research Institute tumor microenvironment Tumor Microenvironment Program Video Yu Yamaguchi Ze'ev Ronai

© Sanford-Burnham Medical Research Institute. All rights reserved.

Get Cloud PHP Hosting on CatN